CORT
Corcept Therapeutics Incorporated
112.90$
-3.9%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 87.3% | 94.3% | 95.5% | 63.8% | 77.2% | 74.5% | 91.7% | 62.9% | 85.6% | 73.8% | 56.1% | 58.0% | |
| 70.0% | 77.9% | 75.0% | 47.2% | 66.3% | 7.6% | 83.4% | 18.3% | 11.4% | 21.8% | 15.2% | 14.4% | |
| 70.0% | 77.9% | 75.0% | 47.2% | 66.3% | 66.9% | 83.4% | 52.8% | 74.0% | 59.2% | 45.6% | 44.5% | |
| 9.6% | 12.0% | 14.3% | 12.8% | 5.6% | 4.8% | 4.6% | 6.8% | 8.0% | 9.1% | 6.9% | 7.1% | |
| 3.5% | 3.2% | 3.4% | 3.8% | 5.2% | 1.3% | 3.7% | 1.2% | 1.0% | 1.2% | 1.5% | 1.5% | |
| 0.7% | 0.2% | 0.3% | 0.2% | 0.2% | 0.3% | 0.3% | 0.2% | 0.3% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 109.8% | 64.4% | 39.8% | 13.4% | 11.5% | 10.0% | 8.5% | 11.3% | 14.0% | 18.5% | 19.1% | 22.6% | |
| 39.1% | 40.2% | 39.8% | 13.4% | 11.5% | 9.4% | 1.8% | 11.2% | 12.4% | 16.8% | 16.7% | 19.9% | |
| 27.2% | 28.8% | 21.3% | – | – | 0.4% | 0.4% | 0.1% | 0.2% | 0.0% | 0.1% | 0.1% | |
| 5.4% | 2.6% | 3.3% | 3.9% | 2.7% | 1.8% | 1.8% | 1.6% | 2.1% | 2.8% | 1.8% | 4.8% | |
| 70.6% | 24.2% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| -9.8% | 35.6% | 60.2% | 86.6% | 88.5% | 90.0% | 91.5% | 88.7% | 86.0% | 81.5% | 80.9% | 77.4% | |
| -935.6% | -636.2% | -468.7% | -87.6% | -37.8% | -5.7% | 14.4% | 46.0% | 50.8% | 64.8% | 64.7% | 76.9% | |
| 291.6% | 205.8% | 168.9% | 56.5% | 40.6% | 29.7% | 21.7% | 29.7% | 19.9% | 18.0% | 13.5% | 14.3% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.